PROTEOME SCIENCES PLC

Report Publication Announcement • Jul 11, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7216K

Proteome Sciences PLC

11 July 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company") 

Notice of Results

Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.

For further information: Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer                         Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson	Tel: +44 (0)20 7220 0500
Tony Quirke (broking) IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan	Tel: +44 (0)20 3053 8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFSIDVILLID